Overview
Investment firm backing biotech and medical innovations.
Founded
2018
Deals · 12mo
0
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Monument Therapeutics | Feb 2025Participated | $1 MOther Equity | |
Atelerix | Jan 2025Led | $1 MOther Equity | |
Pencil Biosciences | Sep 2023Participated | $7 MSeed | |
Kuano | Sep 2023Participated | $2 MSeed | |
PharmEnable | May 2023Participated | $8 MSeries A | |
Alevin Therapeutics | Aug 2022Led | $1 MOther Equity | |
CardiaTec Biosciences | Jul 2022Participated | $2 MSeed | |
Oxford Drug Design | May 2022Participated | $3 MOther Equity | |
Tay Therapeutics | Nov 2021Led | $2 MSeries A | |
Sanome | Sep 2021Participated | $3 MOther Equity | |
Kuano | Jul 2021Participated | $1 MSeed | |
Monument Therapeutics | Jul 2021Participated | $4 MSeed | |
Monument Therapeutics | Feb 2025Participated | $1 MOther Equity | |
Atelerix | Jan 2025Led | $1 MOther Equity | |
Pencil Biosciences | Sep 2023Participated | $7 MSeed | |
Kuano | Sep 2023Participated | $2 MSeed | |
PharmEnable | May 2023Participated | $8 MSeries A | |
Alevin Therapeutics | Aug 2022Led | $1 MOther Equity | |
CardiaTec Biosciences | Jul 2022Participated | $2 MSeed | |
Oxford Drug Design | May 2022Participated | $3 MOther Equity | |
Tay Therapeutics | Nov 2021Led | $2 MSeries A | |
Sanome | Sep 2021Participated | $3 MOther Equity | |
Kuano | Jul 2021Participated | $1 MSeed | |
Monument Therapeutics | Jul 2021Participated | $4 MSeed |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 7 |
| Series A | 1 | 3 |
| Series B | 0 | 1 |
| Other Equity | 2 | 3 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '19 | 1 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 2 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 2 |
| Aug '21 | 0 |
| Sep '21 | 1 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 1 |
| Aug '22 | 1 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 2 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 1 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 17 |
| AI & Machine Learning | 5 |
| Enterprise Software | 1 |
| Food & Agriculture | 1 |
| Professional Services | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 13 |
| $5M-$10M | 3 |
| $10M-$25M | 0 |
| $25M-$50M | 1 |
| $50M-$100M | 0 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 17 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| ACF Investors | 5 |
| Wren Capital | 5 |
| Cambridge Enterprise | 4 |
| Martlet Capital | 4 |
| Meltwind | 4 |
| Parkwalk Advisors | 3 |
| Atlantic Labs | 2 |
| Crista Galli Ventures | 2 |
| Delin Ventures | 2 |
| University of Cambridge | 2 |
| Accel | 1 |
| APEX Ventures | 1 |
| Arrowfield Capital | 1 |
| Ascension Ventures | 1 |
| Astellas Venture Management | 1 |
| BGF | 1 |
| Boston Millennia Partners | 1 |
| Catapult Ventures | 1 |
| GM&C Life Sciences Fund | 1 |
| Heal Capital | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 3 | 18% |
| Participating | 14 | 82% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 2 | 67% |
| Co-led | 1 | 33% |
Team
CEO & Co-Founder